Profile: Matritech Inc. uses its patented proteomics technology to develop diagnostics for the detection of a variety of cancers. We have identified proteins correlated with bladder, cervical, breast, prostate and colon cancers. The NMP22® test kit and NMP22® BladderChek® test, have been approved for both the monitoring & diagnosis of bladder cancer. Our NMP22 products are based on our proprietary nuclear matrix protein (NMP) technology, exclusively licensed from the Massachusetts Institute of Technology, which correlates levels of NMPs in body fluids to the presence of cancer.

The company was founded in 1987, has revenues of USD 1-5 Million. (SEC Filings)